1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Beta Bionics said the FDA cleared its Mint patch pump and that it submitted a 510(k) application for its 3D Intelligence algorithm. It also lowered its 2026 full-year revenue estimate from $131 million to $136 million to $121 million to $126 million, citing a possible deferral of up to $10 million in the fourth quarter as new iLet users may wait for Mint. The filing also discloses a securities class action filed September 4, 2026, which the company says it intends to defend vigorously.
2026 total revenue estimate cut to $121 million to $126 million, from $131 million to $136 million; the company cites a deferral of up to $10 million in Q4 2026
Mint full U.S. commercial launch expected in Q1 2027, ahead of the previous target; manufacturing capacity of at least 1.5 million disposable units in 2027
Expected initial pharmacy coverage of about 40% of insured U.S. lives, rising to at least 50% within the first year of full commercialization
Holtzman v. Beta Bionics, Inc. securities class action filed September 4, 2026 in the Central District of California; potential loss not currently probable or estimable
Evolution Petroleum reported fiscal fourth-quarter 2026 revenue of $24.2 million, up 15% from a year earlier, and net income of $4.6 million, compared with $3.4 million a year earlier. Adjusted EBITDA fell to $6.5 million from $8.6 million, and excluding selected items the company posted an adjusted net loss of $0.6 million versus adjusted net income of $1.1 million a year earlier. The company also declared a $0.12 per share dividend payable September 30, 2026.
Q4 revenue was $24.2 million, up 15% year over year, driven by a 20% increase in average realized prices, partly offset by a 4% drop in production to 6,901 BOEPD.
Q4 net income was $4.6 million, or $0.13 per diluted share, compared with a net loss of $8.9 million in fiscal Q3 2026.
Fiscal 2026 net loss was $2.4 million versus net income of $1.5 million in fiscal 2025; full-year revenue was $86.3 million.
Dividend of $0.12 per share is payable September 30, 2026, to holders of record on September 21, 2026.
Dream Finders Homes entered subscription agreements on September 14, 2026, selling 225,000 shares of Series B Convertible Preferred Stock for $225.0 million, and used the proceeds to redeem its Series A preferred stock. The company also agreed to sell 450,000 more Series B shares at a second closing, contingent on completing its previously announced merger with Beazer Homes USA, Inc., which would fund part of the merger consideration. The preferred stock ranks senior to common stock on dividends and liquidation, carries a 12.00% cumulative dividend, and can convert to Class A common stock at a discount after six years, so it adds a senior claim and potential dilution for common shareholders.
225,000 Series B shares sold at a first closing on September 14, 2026, for an aggregate $225.0 million, with a 2.50% original issue discount
Cumulative dividend of 12.00% per year, payable quarterly, with a maximum rate of 15.00% after step-ups
Additional 450,000 Series B shares to be sold at a second closing tied to the Beazer Homes USA merger conditions
Conversion not permitted by purchasers before the sixth anniversary of the First Closing, except in a Fundamental Change; conversion price floor of $4.19
5E Advanced Materials and its subsidiary 5E SVM agreed on September 14, 2026 to buy specified assets of Searles Valley Minerals and affiliates through a Section 363 sale in Chapter 11 bankruptcy, with consideration of about $3.4 million in cash, 8.3 million common shares, and a promissory note of about $6.2 million. The deal requires Bankruptcy Court approval, Surface Transportation Board authorization for railroad assets, and $10.0 million in bridge financing, and the company expects closing in early October 2026, which would add 8.3 million shares for shareholders and bring operating facilities, but the assets are being acquired as is and the sellers' representations will not survive closing.
5E SVM was selected as successful bidder on September 14, 2026 for assets including Argus, Westend and Trona facilities and about 9,000 acres of Searles Lake brine resources in San Bernardino County, California.
Consideration includes about $3.4 million in cash, 8.3 million shares of common stock, and a senior unsecured promissory note of about $6.2 million; a $300,000 deposit was made.
The company guarantees 5E SVM's cash payment obligation, and the Bridge Facility of $10.0 million carries 8.00% interest with a $1.0 million transaction fee.
The company expects closing in early October 2026; the outside date is October 2, 2026, extendable to October 16, 2026.
Scholar Rock disclosed that the FDA approved ISEMBYLD (apitegromab-mstn) for spinal muscular atrophy in adults and children 2 years and older receiving an SMN2-targeted treatment. The company also corrected management's statement during the September 14, 2026 investor call that the FDA required no post-marketing safety commitments, saying the FDA does require a pregnancy safety study and fracture alert reports.
FDA approved ISEMBYLD for SMA patients aged 2 and older currently on an SMN2-targeted treatment
FDA requires a post-marketing pregnancy safety study covering pregnancy complications and birth outcomes
FDA requested that all serious and non-serious fracture cases be submitted as 15-day alert reports
Correction was made to statements made in error during the September 14, 2026 investor call
Connect Biopharma reported topline results from its 160-patient Phase 2 Seabreeze STAT Asthma study of rademikibart as an add-on to standard of care for acute asthma exacerbations. The primary endpoint, treatment failure over 28 days, did not reach statistical significance (p=0.153), although the company reported a 66% reduction versus placebo, while the key secondary endpoint, post-bronchodilator FEV1 at Day 7, was statistically significant (p=0.023). The company plans to report COPD study data later this month and then meet with the FDA on a Phase 3 program.
Treatment failure rate over 28 days was 2.5% (2 of 79) with rademikibart versus 7.4% (6 of 81) with placebo; p=0.153, not statistically significant
Post-bronchodilator FEV1 on Day 7 rose 250 mL with rademikibart versus 120 mL with placebo, a 130 mL difference (p=0.023)
One serious adverse event was reported in the rademikibart arm versus three in the placebo arm; no AEs led to study discontinuation in either arm
Seabreeze STAT COPD study topline data expected later in September 2026; company plans to engage the FDA on a Phase 3 program afterward
On September 15, 2026, Iridium signed a fourth amendment to its credit agreement, tied to its pending merger with Rocket Lab. The amendment states that the merger will not count as a change of control under the credit agreement, so the term loans can remain outstanding after closing. Certain loan terms become more costly for Iridium only after the merger closes, including higher interest margins, a repricing premium and an exit fee.
The amendment, dated September 15, 2026, is among Iridium, Iridium Satellite LLC, the lenders and Deutsche Bank AG New York Branch as agent.
After closing, term loan rates would be SOFR plus a 2.50% to 3.00% margin, or base rate plus a 1.5% to 2.00% margin, based on Iridium's credit ratings.
After closing, a 1.00% prepayment premium applies to repricing transactions, and a 1.00% exit fee applies to term loans prepaid after the first anniversary of closing.
The merger agreement with Rocket Lab was dated June 28, 2026; the Fourth Amendment's changes take effect only if the merger closes.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.